Trial · NCT05207475
Safety and Efficacy of Remote Ischemic Conditioning on Cerebral Amyloid Angiopathy. (RIC-CAA)
NCT05207475, Not applicable, Unknown, Capital Medical University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Safety and Efficacy of Remote Ischemic Conditioning on Cerebral Amyloid Angiopathy. (RIC-CAA). Trials, record NCT05207475. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05207475
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Safety and Efficacy of Remote Ischemic Conditioning on Cerebral Amyloid Angiopathy. (RIC-CAA)
- NCT number
- NCT05207475
- Status
- Unknown
- Phases
- Not applicable
- Enrollment
- 30 participants, estimated
- Lead sponsor
- Capital Medical University
- Conditions
- Cerebral Amyloid Angiopathy
- Interventions
- Remote ischemic conditioning
- First posted
- 2022-01-26
- Last updated
- 2022-01-26
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Changes of volume of WMHs. | From baseline to 6 months and 1 year treatment. | The volume of WMHs was measured on Flairs at 6months and 12months. |
| Secondary | Adverse events related to RIC treatment. | From baseline to 6 months and 1 year treatment. | Adverse events related to RIC treatment, such as mucocutaneous hemorrhage, changes in coagulation function and so on. |
| Secondary | Incidence of cardio-cerebral vascular events. | From baseline to 6 months and 1 year treatment. | Incidence of cardiovascular and cerebrovascular events,such as Intracranial hemorrhage, subarachnoid hemorrhage, CAA-related transient focal neurological episodes（CAA-TFNEs）, CAA-related Inflammation（CAA-ri），ischemic stroke during follow-up. |
| Secondary | Changes of the cerebral blood flow in MRI ASL. | From baseline to 6 months and 1 year treatment. | Changes of the CBF are assessed by Arterial Spin Labeling (ASL) MRI techniques at 6months and 12months. |
| Secondary | Changes of cognition evaluation on MoCA. | From baseline to 6 months and 1 year treatment. | We used MoCA to evaluate the cognitive functions,of subjects at 6months and 12months, such as memory, execution, visuospatial function and so on. |
| Secondary | Changes of cognition evaluation on TMT tests. | From baseline to 6 months and 1 year treatment. | We used TMT tests to evaluate execution and and so on at 6months and 12months. |
| Secondary | Changes of cognition evaluation on stroop tests. | From baseline to 6 months and 1 year treatment. | We used stroop tests to evaluate execution and and so on at 6months and 12months. |
| Secondary | Changes in evaluation of Timed-Up-and-Go tests. | From baseline to 6 months and 1 year treatment. | We used Timed-Up-and-Go tests to evaluate the gait function of subjects at 6months and 12months. |
| Secondary | Changes of the whole volume of microbleeds. | From baseline to 6 months and 1 year treatment. | The volume of microbleeds was measured on QSM at 6months and 12months. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as |
|---|---|
| Stroop Color-Word Test | Secondary outcome |
Source ConductCognition
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05207475
GET https://conductscience.org/api/trials/v1/NCT05207475/registered